Harvard Bioscience
HBIO
72 hedge funds and large institutions have $74.1M invested in Harvard Bioscience in 2014 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 74 → 72 (-2)
8% less capital invested
Capital invested by funds: $80.6M → $74.1M (-$6.47M)
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
15% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.85M |
| 2 |
HA
Heartland Advisors
Milwaukee,
Wisconsin
|
+$1.38M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
+$1.16M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$810K |
| 5 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$652K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$963K |
| 2 |
GPC
Glacier Peak Capital
Bellevue,
Washington
|
-$925K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$610K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$526K |
| 5 |
Renaissance Technologies
New York
|
-$498K |
HBIO Hedge Fund Activity: Q3 2014 in Review
72 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q3 2014, worth a combined $74.1M — down 8% from $80.6M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HBIO and 11 opened new positions — a net loss of 2 holders — while 24 trimmed existing stakes and 21 added.
The largest buyer was Acadian Asset Management, adding an estimated $1.85M. The largest seller was Northern Trust, cutting an estimated $963K.
- 72 institutional investors held Harvard Bioscience (HBIO) as of Q3 2014, down from 74 in Q2 2014.
- Funds reported $74.1M of Harvard Bioscience stock for Q3 2014, down 8% quarter-over-quarter.
- 11 funds opened new Harvard Bioscience positions in Q3 2014 and 13 closed out, a net change of -2 holders.
- The largest Harvard Bioscience buyer in Q3 2014 was Acadian Asset Management, an estimated $1.85M added.
- The largest Harvard Bioscience seller in Q3 2014 was Northern Trust, an estimated $963K sold.
Based on aggregated 13F filings for Q3 2014.